Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 11 -20 of 28 Show results per page	View Search Criteria \| Help With Results


11.		PRISM (Panitumumab Regimen In Second-Line Monotherapy of Head and Neck Cancer)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20062088 NCT00446446


12.		Study of Addition of Panitumumab to Chemoradiation Therapy in Subjects With Locally Advanced Head and Neck Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20062080 NCT00500760

Last Modified: 12/19/2008 First Published: 10/24/2007


13.		Phase II Randomized Study of Erlotinib Hydrochloride and Gemcitabine Hydrochloride With Versus Without Panitumumab in Patients With Previously Untreated, Metastatic Adenocarcinoma of the Pancreas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Approved-not yet active				18 and over				NCI				NCCTG-N064B N064B, NCT00550836


14.		Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20062079 CONCERT2, NCT00547157

Last Modified: 8/13/2008 First Published: 1/17/2008


15.		Phase II Study of Panitumumab, Chemotherapy, and External-Beam Radiotherapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				18 and over				NCI				NCCTG-N064A N064A, NCT00601627

First Published: 4/8/2008


16.		Phase II Study of Panitumumab and Irinotecan Hydrochloride as Third-Line Therapy in Patients With Previously Treated Metastatic Colorectal Cancer Without KRAS Mutation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 to 80				Other, Pharmaceutical / Industry				GERCOR-PIMABI-C07-1 GERCOR-PIMABI-C07-1, EUDRACT 2007-004806-28, EU-20836, AMGEN-GERCOR-PIMABI-C07-1, NCT00655499

First Published: 9/19/2008


17.		Phase II Study of Neoadjuvant Panitumumab, Docetaxel, Cisplatin, and Radiotherapy Followed By Surgery in Patients With Newly Diagnosed, Locally Advanced Adenocarcinoma of the Distal Esophagus or Gastroesophageal Junction

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Approved-not yet active				Over 18				NCI				ACOSOG-Z4051 Z4051, NCT00757172


18.		PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				20050236 NCT00454779


19.		Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 to 80				Other				EudraCT 2008-002367-14 S-20080081, 2612-3769, NCT00779454


20.		Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				EudraCT 2008-004923-48 S-20080104, LMS 2612-3844, NCT00792363

Select All on One Page


					< Previous 1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute